Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:51:51.725Z.
Calculation as of: 2026-10-06T15:51:51.725Z.
Quote observation: 2026-10-06T15:50:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 97f82c903e8e6ec217280dce7f3fe4a68629f44b5a27270464b7740b55d93be6
PE RATIO
N/A
Market Cap
$374.66M
PE Ratio
N/A
TTM Avg
4952.81
3Y Avg
4952.81
5Y Avg
4952.81
Market Cap
$355.41M
PE Ratio
N/A
TTM Avg
197.33
3Y Avg
88.65
5Y Avg
67.24
Market Cap
$353.62M
PE Ratio
N/A
TTM Avg
170.63
3Y Avg
170.63
5Y Avg
170.63
Market Cap
$380.02M
PE Ratio
N/A
TTM Avg
20.42
3Y Avg
20.42
5Y Avg
20.42
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Opus Genetics, Inc. (IRD) | $365.35M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $360.27M | N/A | 84.67 | 84.67 | 84.67 |
| Canopy Growth Corporation (CGC)vs › | $374.66M | N/A | 4952.81 | 4952.81 | 4952.81 |
| Embecta Corp. (EMBC)vs › | $356.19M | 4.06 | 4.83 | 10.37 | 9.91 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $355.41M | N/A | 197.33 | 88.65 | 67.24 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $354.21M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $353.00M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $353.62M | N/A | 170.63 | 170.63 | 170.63 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $380.02M | N/A | 20.42 | 20.42 | 20.42 |
| Orthofix Medical Inc. (OFIX)vs › | $384.21M | N/A | 157.27 | 122.07 | 183.95 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.42
Forward EPS (Est.)
$-1.04
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
